TTUHSC School of Pharmacy
HomeSOPResearch

Office of Sciences

office_of_sciences_banner

Published Manuscripts

January 1, 2016 - December 31, 2016


Abraham Al-Ahmad

Patel, R., & Al-Ahmad, A. (2016, Apr 12). Growth-factor reduced Matrigel source influences stem cell derived brain microvascular endothelial cell barrier properties. Fluids & Barriers CNS, 13, 6. doi: 10.1186/s12987-016-0030-5.
PMID: 27068644

Clark, P.A., Al-Ahmad, A.J., Qian, T., Zhang, R.R., Wilson, H.K., Weichert, J., . . . Shusta, E.V. (2016, Sep 6). Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood-Brain Barrier Model. Mol Pharm, 13(9), 3341-9. doi: 10.1021/acs.molpharmaceut.6b00441.
PMID: 27421304

Trista Bailey

Bailey, T.A., & Fenney, M. (2016, April). Perceptions of direct-to-consumer advertising and the older adult population. Consult Pharm, 31(4), 215-20. doi: 10.4140/TCP.n.2016.215
PMID:27056358

Amie Blaszczyk

Mahan, R.J., & Blaszczyk, A.T. (2016, Apr). COPD exacerbation and cholinesterase inhibitor therapy in dementia patients. Consult Pharm, 31(4), 221-5. doi: 10.4140/TCP.n.2016.221 
PMID: 27056359

Coulson, E., & Blaszczyk, A.T. (2016, Feb). Assisted living facilities: the next frontier for consultant pharmacists. Consult Pharm, 31(2), 107-11. doi: 10.4140/TCP.n.2016.107. 
PMID: 26842688

Lisa Chastain

Minze, M.G., & Chastain, L.M. (2016, Mar 29). Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide. Ther Clin Risk Manag, 12, 471-8. doi: 10.2147/TCRM.S73579
PMID: 27099505 

Black, R.L., Higbea, A.M., Duval, C.E. & Chastain, L.M. (2016, Aug 13). Pharmacological Management of Obesity in Patients with Type 2 Diabetes. Expert Review of Endocrinology & Metabolism, 11(5), 415-23. DOI: 10.1080/17446651.2016.1220300 [epub ahead of print]

Edwards, K.L., Hadley, R.L., Baby, N., Yeary, J.C., Chastain, L.M., & Brown, C.D. (2016, Aug 27). Utilizing clinical pharmacy specialist to address access to care barriers in the veteran population for the management of diabetes. J Pharm Pract, (epub ahead of print) DOI: 10.1177/0897190016663952
PMID: 27568478

Luca Cucullo

Festoff, B.W., Sajja, R.K., van Dreden, P., & Cucullo, L. (2016, Aug 24). HMGB1 and Thrombin mediate blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease. J Neuroinflammation, 13(1), 194. doi: 10.1186/s12974-016-0670-z.
PMID: 27553758

Kaisar, M.A., Prasad, S., Liles, T., & Cucullo, L. (2016, Jul 15). A decade of e-Cigarettes: Limited research & unresolved safety concerns. Toxicology. 365, 67-75. doi: 10.1016/j.tox.2016.07.020.
PMID: 27477296

Prasad, S., Sajja, R.K., Kaisar, M.A., & Cucullo, L. (2016, Sep). Hyperglycemia exacerbates antiretroviral drug combination induced blood-brain barrier endothelial toxicity. Neurotoxicology. 56, 1-6. doi: 10.1016/j.neuro.2016.06.011. Epub 2016 Jun 23.
PMID: 27345270

Cucullo, L., & Liles, T. (2016, Jun).  Membrane Transporters and Pharmacological Implications. J Pharmacovigil, 4(3). DOI: 10.4172/2329-6887.1000e155
PMID: 27610401

Sajja, R.K., Rahman, S., & Cucullo, L. (2016, Mar). Drugs of Abuse and Blood-Brain Barrier Endothelial Dysfunction: A Focus on the Role of Oxidative Stress. J Cereb Blood Flow Metab, 36(3), 539-54. doi: 10.1177/0271678X15616978. Epub 2015 Nov 17.
PMID: 26661236

Kaisar, M.A., Sajja, R.K., Prasad, S., Abhyankar, V.V., Liles, T., & Cucullo, L. (2016, Oct 26). New experimental models of the blood-brain barrier for CNS drug discovery. Expert Opin Drug Discov. DOI: 10.1080/17460441.2017.1253676 [Epub ahead of print]
PMID: 27782770

Ronald Hall

Minze, M.G., Kwee, Y.Y., & Hall, R.G. (2016, April). Low-molecular-weight heparin prophylaxis dosing: Is weight an issue?. J Pharm Technol, 32(2), 75-80. doi: 10.1177/8755122515617200
PMID: 22973420

Payne, K., & Hall, R.G. (2016). Dosing of antifungals in obesity. Expert Rev Anti Infect Ther, 14(2), 257-67. doi: 10.1586/14787210.2016.1128822. Epub 2015 Dec 28.
PMID: 26641135

Lee GC, Hall RG, Boyd NK, Dallas SD, Du LC, Treviño LB, Retzloff C, Treviño SB, Lawson KA, Wilson J, Olsen RJ, Wang Y, Frei CR. A prospective observational cohort study in primary care practices to identify factors associated with treatment failure in Staphylococcus aureus skin and soft tissue infections. Ann Clin Microbiol & Anitmicrob 2016;15:58. PMID: 27876059

Hall RG 2nd, Pasipanodya JG, Meek C, Leff RD, Swancutt M, Gumbo T. Fractal geometry based decrease in trimethoprim-sulfamethoxazole concentrations in overweight and obese people. CPT Pharmacometrics Syst Pharmacol 2016;5:674-81. PMID: 27869362

Lee GC, Hall RG, Boyd NK, Dallas SD, Du LC, Treviño LB, Retzloff C, Treviño SB, Lawson KA, Wilson J, Olsen RJ, Wang Y, Frei CR. Predictors of community-associated Staphylococcus aureus methicillin resistant- and methicillin susceptible Staphylococcus aureus skin and soft tissue infections in the primary care setting. Epidemiol Infect. 2016;144(15):3198-3204 PMID: 27489019

 

Bethany Ibach

Ibach, B.W., Johnson, P.N., Ernst, K.D., Harrison, D., & Miller, J.L. (2016, Jul 4). Initial dosing and taper complexity of methadone and morphine for treatment of neonatal abstinence syndrome. J Pharm Technol, 32(5), 216-22. doi:10.1177/8755122516657566.

Ibach, B.W., Miller, J.L., Woo, S., Harrison, D., Standifer, K., Hagemann, T.M., & Johnson, P.N. (2016, Jun 29). Characterization of tolerance in children during fentanyl continuous infusions. J Pediatr Intensive Care, 5(3), 79-80. doi:10.1055/s-0036-1584909.

Ibach, B.W., Henry, E.D., & Johnson, P.N. (2016, Mar-Apr). Acute kidney injury in a child receiving vancomycin and piperacillin/tazobactam. J Pediatr Pharmacol Ther, 21(2), 169-75. doi: 10.5863/1551-6776-21.2.169.
PMID: 27199625

Brian Irons

Irons, B., Evans, L., Bogschutz, R., Panasci, K., & Sun, G. (2016, Jul). Utilising Medicare annual wellness visits to implement interprofessional education in the primary care setting. J Interprof Care, 30(4), 529-31. doi: 10.3109/13561820.2016.1152235. Epub 2016 May 24.
PMID: 27219719

Gary Jean

Jean, G.W., Mani, R.M., Jaffry, A., & Khan, S.A. (2016, Apr). Toxic effects of Sorafenib in patients with differentiated thyroid carcinoma compared with other cancers. JAMA Oncol, 2(4), 529-34. doi: 10.1001/jamaoncol.2015.5927.
PMID: 26847808

Jean, G.W., Kelly, K., Mathew, J., Larumbe, E., & Hughes, R. (2016, Aug 20). Venous thromboembolism treatment outcomes in cancer patients and effect of third-party payers on anticoagulant choice. Support Care Cancer. DOI: 10.1007/s00520-016-3377-x [Epub ahead of print]
PMID: 27543162

Vardan Karamyan

Thekkumkara, T., Snyder, R., & Karamyan, V.T. (2016). Competitive binding assay for the G-protein-coupled receptor 30 (GPR30) or G-protein-coupled estrogen receptor (GPER). Methods Mol Biol, 1366, 11-7. doi: 10.1007/978-1-4939-3127-9_2.
PMID: 26585123

Wangler, N.J., Jayaraman, S., Zhu, R., Mechref, Y., Abbruscato, T.J., Bickel, U., & Karamyan, V.T. (2016, Sep 20). Preparation and preliminary characterization of recombinant neurolysin for in vivo studies. J Biotechnol, 234, 105-15. doi: 10.1016/j.jbiotec.2016.07.007. Epub 2016 Aug 2.
PMID: 27496565

Islam, M.R., Yang, L., Lee, Y.S., Hruby, V.J., Karamyan, V.T., & Abbruscato, T.J. (2016, Jul 20). Enkephalin-Fentanyl multifunctional opioids as potential neuroprotectants for ischemic stroke treatment. Curr Pharm Des, [Epub ahead of print].
PMID: 27510489

Sivaramakrishna Koganti

Gao, Z., Sierra, A., Zhu, Z., Koganti, S.R., Subbotina, E., Maheshwari, A., . . . Hodgson-Zingman, D.M. (2016, Mar 10). Loss of ATP-sensitive potassium channel surface expression in heart failure underlies dysregulation of action potential duration and myocardial vulnerability to injury. PloS One, 11(3).  DOI: 10.1371/journal.pone.0151337
PMID: 26964104.

Sierra, A., Subbotina, E., Zhu, Z.,  Gao, Z., Koganti, S.R., Coetzee, W.A., . . . Zingman, L.V. (2016, Feb 26). Disruption of ATP-sensitive potassium channel function in skeletal muscles promotes production and secretion of musclin. Biochem Biophys Res Commun, 471(1), 129-34. doi: 10.1016/j.bbrc.2016.01.166. Epub 2016 Jan 30. 
PMID: 26828268.

Irene La-Beck

Petersen, G., Alzghari, S.K., Chee, W., Sankari, S., & La-Beck, N.M.(2016, Jun 28). Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J Control Release, 232, 255-64. doi: 10.1016/j.jconrel.2016.04.028. Epub 2016 Apr 22.
PMID: 27108612

Lowe, D.B. & La-Beck, N.M. (2016, April 6) Epithelial-mesenchymal transition as a potential biomarker for identifying responders to immune checkpoint inhibitor therapy in lung adenocarcinoma. Translational Cancer Research, 5(2), 208-10. doi: 10.21037/tcr.2016.04.01

Young Lee

Vega, J.A., Lee, Y.R., McMahan, D., Duong, H.Q. (2016, Jun 24). Monitoring enoxaparin with antifactor Xa levels in severe renal impairment. J Pharm Care Health Sys, 3(2),161. doi:10.4172/2376-0419.1000161

Lee, Y.R., Wilson, E., & Preston, P. (2016, Apr 4). Dronedarone-induced pulmonary toxicity: A case report and literature review. J Hosp & Clin Pharm, 2(2):70-75.

Akundi, S., Lee, Y.R., Perry, G.K., Fike, D.S., & Mnjoyan, S. (2015, Dec). Nephrotoxicity in recipients of vancomycin vs. vancomycin with vitamin C. Int J Med and Pharm, 3(2), 1-15.  DOI: 10.15640/ijmp.v3n2a1

Devin Lowe

Lowe, D.B. & La-Beck, N.M. (2016, April 6) Epithelial-mesenchymal transition as a potential biomarker for identifying responders to immune checkpoint inhibitor therapy in lung adenocarcinoma. Translational Cancer Research, 5(2), 208-10. doi: 10.21037/tcr.2016.04.01

Eric MacLaughlin

Haines, S.T., Sicat, B.L., Haines, S.L., MacLaughlin, E.J., & Van Amburgh, J.A. (2016) Processes and metrics to evaluate faculty practice activities: a survey of US colleges/schools of pharmacy. Am J Pharm Educ, 80(4), Article 60. doi: 10.5688/ajpe80460.

Zorek, J.A., Fike, D.S., Eickhoff, J.C., Engle, J.A., MacLaughlin, E.J., Dominguez, D.G., Seivert, C.S. (2016). Refinement and validation of the student perceptions of physician-pharmacist interprofessional clinical education instrument. Am J Pharm Educ, 80(3), Article 47. doi: 10.5688/ajpe80347.

Becky Mahan

Mahan, R.J., & Blaszczyk, A.T. (2016, Apr). COPD Exacerbation and cholinesterase therapy in dementia patients. Consult Pharm, 31(4), 221-5. doi: 10.4140/TCP.n.2016.221.
PMID: 27056359

Livia McCutcheon (Macedo)

Agness-Whittaker, C.F., & Macedo, L. (2016). Aging, culture, and health communication: exploring personal cultural health beliefs and strategies to facilitate cross-cultural communication with older adults. MedEdPORTAL Publications, 12, 10374.
http://dx.doi.org/10.15766/mep_2374-8265.10374

Chephra McKee

McKee, C., & Bohannon, K. (2016, Mar-Apr). Exploring the reasons behind parental refusal of vaccines. J Pediatr Pharmacol Ther, 21(2), 104-9. doi: 10.5863/1551-6776-21.2.104.
PMID: 27199617

Constantinos Mikelis

O'Hayre, M., Inoue, A., Kufareva, I., Wang, Z., Mikelis, C.M., Drummond, R.A., . . . Gutkind, J.S. (2016, Jul 21). Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells. Oncogene, 35(29), 3771-80. doi: 10.1038/onc.2015.442. Epub 2015 Nov 30.
PMID: 26616858 

Punganuru, S.R., Madala, H.R., Venugopal, S.N., Samala, R., Mikelis, C., & Srivenugopal, K.S. (2016, Jan 1). Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties. Eur J Med Chem, 107,233-44. doi: 0.1016/j.ejmech.2015.10.052. Epub 2015 Nov 2.
PMID: 26599530

Molly Minze

Minze, M.G., Kwee, Y.Y., & Hall, R.G. (2016, Apr). Low-molecular-weight heparin prophylaxis dosing: Is weight an issue?. J Pharm Technol, 32, 75-80. doi: 10.1177/8755122515617200

Kenna Payne

Payne, K., & Hall, R.G. (2016, Dec 28). Dosing of antifungal agents in obese people. Expert Rev Anti Infect Ther, 14(2), 257-67. doi: 10.1586/14787210.2016.1128822.
PMID: 26641135

Rebecca Schoen

Schoen RR, Gallimore CE. Why Pharmacists Should Be Facilitators of Mental and Physical Health Within Patient. Centered Medical Homes. JPSW. Mar/Apr 2016

Meredith Sigler

Daniels K, Sigler M, Kirk S, Brittain K. Management of patient with prediabetes: is it more than just watchful waiting? Palmetto Pharmacist. 2016;56(1):16-26.

Quentin Smith

Samala, R., Thorsheim, H.T., Goda, S., Taskar, K., Gril, B., Steeg, P.S., & Smith, Q.R. (2016, Aug 19). Vinorelbine delivery and efficacy in the MDA-MB-231BR preclinical model of brain metastases of breast cancer. Pharm Res. doi: 10.1007/s1109501620123 [Epub ahead of print]
PMID: 27541873

Sanjay K. Srivastava 

Fofaria, N.M., Qhattal, H.S., Liu, X., & Srivastava, S.K. (2016, Feb 10). Nanoemulsion formulations for anti-cancer agent piplartine-Characterization, toxicological, pharmacokinetics and efficacy studies. Int J Pharm, 498(1-2), 12-22. doi: 10.1016/j.ijpharm.2015.11.045.
PMID: 26642946

Ranjan. A., Gupta, P., & Srivastava, S.K. (2016, Feb 15). Penfluridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis. Cancer Res, 76(4), 877-90. DOI: 10.1158/0008-5472.CAN-15-1233
PMID: 26627008

Ranjan, A., & Srivastava, S.K. (2016, May 18). Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis. Sci Rep, 6, 26165. DOI: 10.1038/srep26165
PMID:27189859

Kalkunte Srivenugopal

Basak, D., Punganuru, S.R., & Srivenugopal, K.S. (2016, Apr). Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor. Int J Oncol, 48(4), 1426-36. doi: 10.3892/ijo.2016.3372. PMID: 26848023

Punganuru, S.R., Madala, H.R., Venugopal, S.N., Samala, R., Mikelis, C., & Srivenugopal, K.S. (2016, Jan 1). Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties. Eur J Med Chem, 107,233-44. doi: 0.1016/j.ejmech.2015.10.052. Epub 2015 Nov 2.
PMID: 26599530

Thomas Thekkumkara

Thekkumkara, T., Snyder, R., & Karamyan, V.T. (2016). Competitive binding assay for the G-protein-coupled receptor 30 (GPR30) or G-protein-coupled estrogen receptor (GPER). Methods Mol Biol, 1366, 11-7. doi: 10.1007/978-1-4939-3127-9_2.
PMID: 26585123

Paul Trippier

Kinarivala, N., Suh, J.H., Botros, M., Webb, P., & Trippier, P.C. (2016, Apr 15). Pharmacophore elucidation of phosphoiodyn A-Potent and selective peroxisome proliferator-activated receptor β/δ agonists with neuroprotective activity. Bioorg Med Chem Lett, 26(8), 1889-93. doi:10.1016/j.bmcl.2016.03.028. Epub 2016 Mar 9
PMID: 26988304

Verma, K., Zang, T., Gupta, N., Penning, T.M., & Trippier, P.C. (2016, Jun 22). Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines. ACS Med Chem Lett, 7(8), 774-9. DOI: 10.1021/acsmedchemlett.6b00163
PMID: 27563402

Trippier, C.(2016). Selecting good ‘drug-like’ properties to optimize small molecule blood-brain barrier penetration. Curr Med Chem, 23(14)1392-407.
PMID: 27048339

Kinarivala, N., & Trippier, P.C. (2016, May 26). Progress in the development of small molecule therapeutics for the treatment of Neuronal Ceroid Lipofuscinoses. J Med Chem, 59(10), 4415-27. DOI: 10.1021/acs.jmedchem.5b01020
PMID: 26565590

Kinarivala, N., Shah, K., Abbruscato, T.J., & Trippier, P.C. (2016, Oct 10). Passage variation of PC12 cells results in inconsistent susceptibility to externally induced apoptosis. ACS Chem Neurosci, DOI: 10.1021/acschemneuro.6b00208 [Epub ahead of print]
PMID: 27718545

Ming-Hai Wang

Feng, L., Yao, H.P., Sharma, S., Zhou, Y.Q., Zhou, J., Zhang, R., & Wang, M.H. (2016, Jun 17). Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res, 35(1), 95. DOI: 10.1186/s13046-016-0364-5
PMID: 27316712

Yao, H.P., Feng, L., Zhou, J.W., Zhang, R.W., & Wang, M.H. (2016, May 1). Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. Am J Cancer Res, 6(5), 937-56.
PMID: 27293990

Wei Wang

Qin, J.J., Wang, W., Sarkar, S., & Zhang, R. (2016, Sep 10). Oral Delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. J Control Release, 237, 101-14. doi: 10.1016/j.jconrel.2016.07.008. Epub 2016 Jul 6.
PMID: 27394681

Ruiwen Zhang

Wang, W., Nag, S., & Zhang R. (2016). Pharmacokinetics and Pharmacodynamics in Breast Cancer Animal Models. Methods Mol Biol, 1406, 271-87. doi: 10.1007/978-1-4939-3444-7_23. 
PMID: 26820963

Qin, J.J., Wang, W., Sarkar, S., & Zhang, R. (2016, Sep 10). Oral Delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. J Control Release, 237, 101-14. doi: 10.1016/j.jconrel.2016.07.008. Epub 2016 Jul 6.
PMID: 27394681

Wang, W., Nijampatnam, B., Velu, S.E., & Zhang, R. (2016, Mar 3). Discovery and development of synthetic tricyclic pyrroloquinone alkaloid analogs for human cancer therapy.Front Chem Sci Eng, 10(1), 1-15. doi:10.1007/s11705-016-1562-6

Qin, J.J., Wang, W., Sarkar, S., Voruganti, S., Agarwal, R., & Zhang, R. (2016, May 31). Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. Oncotarget, 7(22), 32566-78. doi: 10.18632/oncotarget.8873.
PMID: 27105525

Yu, J., Li, Z., Wang, W., Zhang, Y., Li, D., Liu, Y., . . . Zhang, R. (2016, Jun 1). Anticancer 20(R)-dammarane-3β,12 β,20,25-tetrol-loaded polymericmicelles: Preparation, quantification and pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci, 1022, 13-20. doi: 10.1016/j.jchromb.2016.03.045. Epub 2016 Apr 1.
PMID: 27070116

Qin, J.J., Sarkar, S., Voruganti, S., Agarwal, R., Wang, W., & Zhang, R. (2016, Jul). Identification of Lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy. J Biomed Res, 30(4), 322-33. doi: 10.7555/JBR.30.20160018. Epub 2016 May 25.
PMID: 27533941

Feng, L., Yao, H., Zhou, Y.Q., Zhou, J., Zhang, R., & Wang, M.H. (2016, Apr 22). Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res, 35, 70. DOI 10.1186/s13046-016-0347-6.
PMID: 27102688

Yao, H.P., Feng, L., Zhou, J.W., Zhang, R.W., & Wang, M.H. (2016, May 1). Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. Am J Cancer Res, 6(5), 937-56.
PMID: 27293990

 Published Book Chapters/ Editorials/ Commentaries

January 1, 2016 - December 31, 2016

Brian Irons

Irons, B. (2016). Endocrine and Metabolic Disorders. In: Burke J, Cauffield J, El-Ibiary S, et al. eds. (2016 Eds.), Updates in Therapeutics: The Pharmacotherapy Preparatory and Recertification Course, 199-251, Lenexa, KS: American College of Clinical Pharmacy.

Eric MacLaughlin

Saseen, J.J., & MacLaughlin, E.J.(2016). Chapter 3, Hypertension. In: Dipro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, (10th eds.) Pharmacotherapy: A Pathophysiologic Approach. New York, NY: McGraw-Hill. (in press).

Thomas Parker

Parker, T.M. (2016, March). Pediatric Endocrine and Metabolic Disorders. In: American College of Clinical Pharmacy, Updates in Therapeutics®: Pediatric Pharmacy Preparatory Review and Recertification Course (2016 Eds.). Kansas City, MO: American College of Clinical Pharmacy

Paul Trippier 

Trippier, P.C. (2016). Editorial: Small molecule drug discovery for pediatric diseases. Mini Rev Med Chem, 16(6), 428-9.
PMID: 26853978

Ruiwen Zhang

Zhang, R.W. (2016, Jan). Artemisinin (Qing Hao Su), Nobel Prize, anti-malaria, and beyond. Chin J Nat Med, 14(1), 1-2. doi: 10.3724/SP.J.1009.2016.00001.
PMID: 26850339

Archived Publications:

2015 Publications

 

Content updated 7/6/16

©